대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Clinical trial of allogeneic mesenchymal stem cell therapy for chronic active antibody-mediated rejection in kidney transplant recipients
저자	Hyung Duk Kim,Hyunjoo Bae,Soung Eun Kim,Sang Hun Eum,Hanbi Lee,Eun Jeong Ko,Chul Woo Yang,Eun-Jee Oh,Byung Ha Chung
출판정보	2022; 2022(1):
키워드
초록	Objectives: The aim of this study is to investigate the therapeutic effect of allogenic mesenchymal stem cell therapy (MSC) in kidney transplant recipients (KTR) diagnosed with chronic active antibody-mediated rejection (CAMR). Methods: A total of 5 patients diagnosed with CAMR by allograft biopsy were enrolled. Each patient received MSC for 4 cycles (1×106 cells/kg every other week) via peripheral vein. Human bone marrow-derived MSC (Catholic MASTER Cells) were obtained from the Catholic Institute of Cell Therapy (CIC, Seoul, Korea). The Catholic MASTER Cells were certified by the KFDA. Blood samples were collected at baseline and before 2nd and 4th MSC doses, and 1, 3, and 6 months after the end of treatment. Routine blood chemistry tests including serum creatinine, third party donor-specific Elispot and lymphocyte subsets analysis were performed using blood samples. Results: Of the total of 5 patients, 2 patients maintained their allograft function well during the follow-up period. Two of the three patients who experienced graft loss started hemodialysis. The other patient developed Pneumocystis jirovecii pneumonia (PJP) 5 weeks after treatment, and expired on Week 6. There were no infectious complications other than PJP, and there were no serious adverse events related to MSC administration. In the flow cytometry results, CD8+CCR7+ T cells, CD3Vδ2 T cells and Vδ2+γδ T cells decreased after MSC administration, and CD8+CCR7- T cells, CD3Vδ1 T cells and Vδ1+γδ T cells showed a conversely increasing trend. The two patients who maintained allograft function showed lower baseline serum creatinine levels compared to the other patients. In addition, these patients had an average baseline Elispot of less than 10 spots/2.5x105 cells, which was lower than that of patients with graft loss. Conclusions: MSC showed the therapeutic effect on CAMR in some patients through changes in immune cells. And further studies are required on the MSC.
원문(PDF)	PDF 원문보기

목록

위로가기